100 related articles for article (PubMed ID: 21520246)
1. Amelioration of systemic lupus erythematosus by Withangulatin A in MRL/lpr mice.
Sun L; Zhou L; Chen M; Zhong R; Liu J
J Cell Biochem; 2011 Sep; 112(9):2376-82. PubMed ID: 21520246
[TBL] [Abstract][Full Text] [Related]
2. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
[TBL] [Abstract][Full Text] [Related]
4. KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, is a novel compound to be effective on mouse systemic lupus erythematosus.
Lee GH; Oh JM; Kim HS; Yoon WK; Yi KY; Yang Y; Han SH; Lee S; Moon EY
Eur J Pharmacol; 2011 Oct; 668(3):459-66. PubMed ID: 21827747
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
6. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
7. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice.
Ju ZL; Shi GY; Zuo JX; Zhang JW;
Immunology; 2007 Feb; 120(2):281-9. PubMed ID: 17073941
[TBL] [Abstract][Full Text] [Related]
8. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
[TBL] [Abstract][Full Text] [Related]
10. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
Jimenez-Caliani AJ; Jimenez-Jorge S; Molinero P; Rubio A; Guerrero JM; Osuna C
J Pineal Res; 2008 Sep; 45(2):204-11. PubMed ID: 18507713
[TBL] [Abstract][Full Text] [Related]
11. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice.
Song YC; Tang SJ; Lee TP; Hung WC; Lin SC; Tsai CY; Ng WV; Wu MF; Sun KH
Arthritis Rheum; 2010 Aug; 62(8):2401-11. PubMed ID: 20506162
[TBL] [Abstract][Full Text] [Related]
12. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice.
Hagiwara E; Okubo T; Aoki I; Ohno S; Tsuji T; Ihata A; Ueda A; Shirai A; Okuda K; Miyazaki J; Ishigatsubo Y
Cytokine; 2000 Jul; 12(7):1035-41. PubMed ID: 10880249
[TBL] [Abstract][Full Text] [Related]
13. Effect of combining ACE inhibitor and statin in lupus-prone mice.
Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
[TBL] [Abstract][Full Text] [Related]
14. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies.
Liang B; Gee RJ; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 1999 Aug; 163(4):2322-9. PubMed ID: 10438978
[TBL] [Abstract][Full Text] [Related]
15. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-beta1 in the MRL/lpr lupus mouse model.
Kaplan J; Woodworth L; Smith K; Coco J; Vitsky A; McPherson J
Lupus; 2008 Sep; 17(9):822-31. PubMed ID: 18755864
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
18. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
Yu C; Chen S; Zhou B; Zhang H; Su X; Luo Y; Yang L
Mol Immunol; 2021 Jan; 129():1-11. PubMed ID: 33254074
[TBL] [Abstract][Full Text] [Related]
19. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
20. [Functional analysis of an autoantigen reactive B cell clone derived from MRL/MP-lpr/lpr mice].
Kobayashi K; Hamano T; Kakishita E
Ryumachi; 1996 Dec; 36(6):844-55. PubMed ID: 9122824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
